Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06516510 · ClinicalTrials.gov registry record · Early Phase 1
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
A Early Phase 1 study, sponsored by Blue Earth Therapeutics.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT06516510 is a Early Phase 1 study that was terminated before completion, run by Blue Earth Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT06516510, a Early Phase 1 study, was terminated before completion, sponsored by Blue Earth Therapeutics.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
Interventions
- DRUG lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2025-08-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06516510
The ClinicalTrials.gov registry entry for NCT06516510 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blue Earth Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lutetium (177Lu) rhPSMA 10.1 and Pluvicto® is the first listed.
NCT06516510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06516510 about?
NCT06516510 is a clinical study titled "A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer". A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
What is the current status of trial NCT06516510?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2024-10-31. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT06516510?
The interventions under investigation include: lutetium (177Lu) rhPSMA 10.1 and Pluvicto® (DRUG).
Who is sponsoring clinical trial NCT06516510?
This trial is sponsored by Blue Earth Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.